New drug duo aims to wipe out esophageal tumors before surgery
NCT ID NCT07627347
First seen Jun 06, 2026 · Last updated Jun 18, 2026 · Updated 4 times
Summary
This study tests whether giving two drugs (anlotinib and bemocizumab) before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. About 25 adults with stage II-IIIB disease will receive the combination, then undergo surgery. The main goal is to see if the drugs can eliminate all cancer cells by the time of surgery, potentially leading to better long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.